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CASE PRESENTATION
A 67-year-old Caucasian woman was admitted to our
hospital with progressive shortness of breath and swelling
of all four extremities. Her past medical history included
type 2 diabetes and hypertension of approximately 20 and
10 years of duration, respectively, hypothyroidism, morbid
obesity, paroxysmal atrial fibrillation, and sciatica. She
denied a history of diabetic nephropathy or retinopathy. On
questioning, she noted that over the previous 4 months she
had developed new onset of lower extremity edema,
increasing abdominal girth, and approximately 60 lb weight
gain. More recently over the 3 weeks before admission, she
had developed new onset of orthopnea and dyspnea with
minimal exertion. She denied any recent history of chest
pain, fever, foamy urine, or leg pain. Medications at the
time of admission included lopressor 50 mg daily, lisinopril
10 mg daily, hydrochlorothiazide 50 mg daily, furosemide
40 mg daily, repaglinide 2 mg daily, rosiglitazone 8 mg daily,
gabapentin 200 mg twice daily, and levothyroxine 200mg
daily. Except for the gabapentin, which had been added 3
weeks before admission for her sciatica, she had been on
stable dosing of her other medications for the previous
several months. Rosiglitazone had been added
approximately 36 months before the current presentation.
The prescribing physician had not recorded a baseline
weight at that time. She had not been treated with insulin
for her diabetes, and she had not taken any non-steroidal
anti-inflammatory agents in the previous few months.
Pulse oximetry revealed an oxygen saturation of 90% while
breathing room air, which increased to 100% while
breathing supplemental oxygen at a rate of 2 l/min. She
was afebrile, and her blood pressure was 120/70 mm Hg.
On examination, she was anxious, visibly short of breath,
and unable to complete full sentences. She was markedly
obese. She had crackles in both lung fields up to the apices.
She had deep pitting edema of the arms, legs, anterior
abdominal wall, and pre-sacral areas.
Heart sounds were distant. Examination of the head and
neck, skin, and joints and lymph nodes was unremarkable.
Electrocardiogram showed sinus tachycardia at a rate of
100 bpm. Portable chest X-ray (CXR) showed cardiomegaly
and perihilar edema consistent with congestive heart
failure (Figure 1). Ultrasound of the lower extremities
showed no evidence of deep venous thrombosis and a
ventilation-perfusion (V/Q) scan showed no evidence of
pulmonary embolism. Patient laboratory data are
indicated in Table 1.
HOSPITAL COURSE AND CLINICAL FOLLOW-UP
She was admitted with a diagnosis of new onset of congestive
heart failure (CHF) and was started on intravenous
furosemide 40 mg twice a day. Transthoracic echogram was
non-diagnostic due to the patient’s body habitus and poor
acoustic penetration. Transesophageal echocardiogram
showed mild left ventricular hypertrophy, normal left
ventricular systolic function, and impaired mitral filling
consistent with diastolic dysfunction. Right heart catheter-
ization was performed (Table 2). The etiology of the patient’s
biventricular pressure/volume overload was not immediately
apparent. Thiazoledinedione-induced fluid retention was
considered, and hence rosiglitazone was discontinued.
Neseritide was added as a continuous infusion at a rate of
0.01 mg/kg/min to enhance natriuresis in the setting of
elevated pulmonary capillary wedge pressure with preserved
left ventricular systolic function. In addition, spironolactone
was started at 25 mg twice daily. She sustained a net negative
fluid balance of approximately 1.5 kg/day, with improvement
in symptoms. Neseritide was discontinued after 5 days. She
was discharged home on the tenth hospital day, having lost
15 kg since admission. Medications at the time of discharge
included furosemide 40 mg p.o. twice daily, spironolactone
25 mg p.o. twice daily, acetazolamide 250 mg p.o. twice daily
(added because of the development of mild metabolic
alkalosis), metoprolol XL 50 mg p.o. twice daily, levothyroxine
200 mg p.o. twice daily, and repaglinide 1 mg p.o. twice
daily. Acetazolamide was stopped three weeks after hospital
discharge. During subsequent clinic follow-up visits, she was
noted to experience ongoing weight loss and resolution of her
edema. At the 4-month mark following the initial diagnosis
of CHF, her weight had decreased by 54 kg (from the
admission weight of 142 kg down to 88 kg).
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CLINICAL DIAGNOSIS
Rosiglitazone-induced fluid retention leading to biventricular
pressure and volume overload, CHF, and anasarca.
DISCUSSION
In this complex patient with new onset of symptomatic CHF,
one has to consider a broad differential diagnosis. The patient
had several risk factors predisposing to diastolic dysfunction,
including long-standing hypertension, obesity, and type 2
diabetes. The development of her symptoms cannot be
attributed to myocardial ischemia or myocarditis, given the
absence of chest pain or abnormal electrocardiogram
findings, normal troponin levels, and predominantly diastolic
dysfunction with absence of segmental wall motion abnor-
malities on transesophageal echocardiogram. There was also
no evidence of significant valvular disease or pericardial
disease. Metabolic causes, such as hemochromatosis or
amyloidosis, were also unlikely given the absence of other
clinical factors. Because of her obesity, the patient was at high
risk for obstructive sleep apnea, which potentially could have
contributed to her hypertension and heart failure. Although a
formal sleep study has never been performed, the fact that
her symptoms resolved without specific sleep apnea therapy
supports the exclusion of this cause. She also denied using
non-steroidal anti-inflammatory drugs and has not been
treated with calcium channel blockers before admission.
Although mild weight gain and lower extremity edema have
been previously reported with gabapentin use,1 there are no
reports of CHF, pulmonary edema, or fluid retention with
this medication. The patient had a history of mild anemia
with normal iron, B12, and folate levels. The pattern of
hemoglobin change over time (Table 1) is consistent with
hemodilution from massive volume retention. Within 4
months of stopping rosiglitazone and with resolution of
CHF, her hemoglobin had normalized without iron or
erythropoietin therapy. The temporal sequence of events
points to a long-standing thiazolidinedione (TZD)-induced
fluid retention as the most likely cause of this patient’s
presentation. Although the time course for development of
symptomatic CHF in this patient since initiation of
rosiglitazone (approximately 3 years) is longer than reported
in most other studies, a thorough clinical evaluation upon
hospitalization was unable to identify any other likely
causative factor(s) to explain this patient’s marked fluid
retention and CHF. This causal relationship is further
supported by the swift resolution of the patient’s symptoms
after discontinuation of rosiglitazone therapy, and main-
tenance of a stable weight on long-term follow up. We
postulate that the process of gradual fluid retention was
Figure 1 | Portable AP view of the chest demonstrates
cardiomegaly, perihilar edema, and blunting of the left
costophrenic angle, consistent with congestive heart failure.
Table 1 | Laboratory results
Test
4 months before
admission Date of admission
4 months after
discharge Reference range
Blood urea nitrogen (mg/dl) 17 38 18 7–20
Creatinine (mg/dl) 0.6 1.2 0.7 0.5–0.9
WBC (109/l) 6.0 3.5–9.0
Hemoglobin (g/dl) 10.7 8.8 12.1 12.0–15.0
Platelet (109/l) 217 165–415
Albumin (g/dl) 3.7 3.8 4.0–5.0
Cholesterol (mg/dl) 164 o200
TSH (mU/ml) 5.38 0.3–4.2
BNP (pg/ml) 338 72 o100
Fe (mg/dl) 46 46 41–141
TIBC (mg/dl) 327 422 251–406
Ferritin (ng/ml) 94 49 10–150
B12 (pg/ml) 1522 279–996
Folate (ng/ml) 19 5.4–18.0
Spot urine protein (mg/dl) 24
Spot urine creatinine (mg/dl) 132
Troponin Normal  3 over 24 h
Urine dipstick Negative for protein or blood
Urine microscopy No hematuria or pyuria
BNP, brain natriuretic peptide; TSH, thyroid-stimulating hormone; WBC, white blood cells.
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probably facilitated by the patient’s background physiology of
diastolic dysfunction from hypertension, and possibly sleep
apnea.
The goal of this report is to review the recently discovered
mechanisms of TZD-induced edema and to relate these
discoveries to clinical practice. We will begin by briefly
reviewing the clinical use of TZDs and their peroxisome
proliferator-activated receptor (PPAR)-mediated effects.
Clinical use of TZDs
TZDs are widely used to treat type II diabetes. Their
mechanism of action is attributed to binding and activation
of the PPAR-g. Three drugs in this class have been studied
extensively in humans: troglitazone, rosiglitazone, and
pioglitazone. Troglitazone was approved in the United States
in January 1997 as the first PPAR-g agonist for treatment of
type 2 diabetes. The approval of rosiglitazone and pioglita-
zone followed in 1999. Troglitazone was withdrawn from the
market in March 2000, because of reports of liver toxicity.
Hepatotoxicity associated with rosiglitazone and pioglitazone
is rare, and these drugs are currently in widespread clinical
use worldwide. Both drugs at maximal doses lead to an
absolute decrease in glycosylated hemoglobin of approxi-
mately 1–1.5%.2 Given the often suboptimal results from the
use of other oral glucose-lowering agents alone or in
combination, the use of TZDs has been increasing steadily.
In addition, the recent publication of the DREAM trail (The
Diabetes Reduction Assessment with ramipril and rosigli-
tazone Medication) is likely to extend the use of TZDs to the
pre-diabetic population. In this large, prospective, rando-
mized, international controlled trail, rosiglitazone at 8 mg
daily for 3 years significantly reduced the incidence of new
onset of type II diabetes in adults with impaired fasting
glucose or impaired glucose tolerance.3 Fluid retention, as
illustrated by our case, is the most serious potential side effect
of currently available TZDs.
TZDs and PPARs
PPARs are recently discovered nuclear transcription factors
essential to the control of energy metabolism that are
modulated via binding with tissue-specific fatty acid
metabolites.2 Of the three PPAR isoforms, a and g have
been extensively studied. Less is known about PPAR-d.
PPAR-a is predominantly found in liver, muscle, and
vascular endothelial cells. PPAR-g is expressed at high levels
in adipose and liver tissues, macrophages, and pancreatic-b
cells. PPAR-g exerts its biologic effects via the processes of
transactivation or transrepression. In transactivation, PPAR-g
interacts with the retinoid X receptor within the cell nucleus;
following tissue-specific ligand activation, this leads to the
regulation of target genes via interaction with specific DNA
promoter regions, termed PPAR response elements. In
transrepression, ligand binding with PPAR-g leads to direct
inhibition of signal transduction pathways in a DNA
binding-independent manner. Multiple biologic pathways
have been demonstrated to be influenced by PPAR-g
stimulation. Beyond the metabolic syndrome, TZDs have
been proposed as potential therapeutic modulators of
atherosclerosis,4 sepsis and inflammation,5 cancer,6 non-
alcoholic fatty liver disease,7 polycystic ovarian syndrome,8
and HIV-associated lipodystrophy.9 PPAR-g stimulation
results in increased glucose transport in target tissues, as
well as enhanced insulin sensitivity in liver and adipose tissue
leading to decreased release of glucose and free fatty acids
into the circulation. Troglitazone and rosiglitazone are pure
PPAR-g agonists, whereas pioglitazone is primarily a PPAR-g
agonist and has some PPAR-a activity as well. Fibric acid
derivatives, such as gemfibrozil and fenofibrate, exert their
lipid-lowering effect via PPAR-a activation. Muraglitazar, a
combined PPAR-a and -g agonist, has been under active
investigation. However, a recently published pooled analysis
of clinical experience with this agent suggests that it carries
an excessive risk of cardiovascular events.10 Currently
available PPAR agonists and their targets are summarized
in Table 3.
TZDs and fluid retention
Weight gain of 1–3 kg is common in patients taking long-
term TZDs when used alone or in combination with other
oral glucose-lowering agents. Greater weight gains of 4–5 kg
may be seen, however, when TZDs are used in combination
with insulin therapy. Although a portion of the weight gain
may be related to a redistribution of body fat stores from
visceral to subcutaneous areas, the majority is probably the
result of renal-mediated fluid retention, leading to an
increase in plasma volume of approximately 1.8 ml/kg.11
This increase in plasma volume may be accompanied by a
mild dilutional anemia, and in some patients, the develop-
ment of pedal edema or overt symptoms of CHF. Clinical
studies have shown that edema develops in approximately
3–5% of patients taking TZDs, with the incidence increasing
to 10–15% in those receiving concurrent insulin therapy. This
heightened susceptibility to the development of weight gain
and edema has been attributed to the fact that insulin-
requiring patients tend to be older and have a greater
incidence of microalbuminuria, coronary artery disease, and
left ventricular hypertrophy, all conditions which may be
associated with fluid retention.
Early clinical data suggested a relatively low incidence of
CHF (B1%) in patients treated with TZD monotherapy,
increasing 2–3% in those patients receiving insulin in
addition to a TZD. Soon after the introduction of TZDs
Table 2 | Right heart catheterization data
Measurements Value Normal values
Right atrium (mm Hg) 27 0–6
Pulmonary artery (mm Hg) 65/35 25/10
Pulmonary capillary wedge
pressure (mm Hg)
28 8–12
Cardiac output (l/min) 5.53 4.0–8.0
Cardiac index (l/min/m2) 2.76 2.5–4.0
Mixed venous oxygen saturation (%) 66 60–75
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into clinical practice in the late 1990s, however, multiple case
reports appeared suggesting a possible causal link between
TZD use and new onset CHF (reviewed by Nesto et al.11).
Weight gain, edema, and CHF with TZD use appear to be
both dose- and time-dependent. Case reports have described
the development of CHF as early as 1 month after TZD
initiation, and up to 12 months later. Subclinical develop-
ment of CHF may be difficult to appreciate by history and
exam, and some investigators have suggested the possible
utility of serial brain natriuretic peptide monitoring during
TZD treatment as a means of detecting early, asymptomatic
CHF.12
Several large, retrospective analyses have yielded conflict-
ing results regarding whether TZD use independently
predicts index hospitalization for CHF.13–15 Nevertheless,
the American Heart Association and the American Diabetes
Association published a joint consensus statement on TZD
use and the risk of development of CHF in 2003.11 The major
recommendations included the following: (1) that TZD use
should be avoided in patients with pre-existing New York
Heart Association (NYHA) class III or IV CHF; (2) that the
medications should be initiated at the lowest dose possible in
patients with established NYHA class I or II CHF, asympto-
matic left ventricular dysfunction, or at least one other risk
factor besides diabetes for CHF; (3) that patients should be
monitored carefully for evidence of weight gain or edema,
and dose escalation should be performed gradually. Con-
current insulin treatment, although included as a risk factor
for fluid retention, was not contraindicated by the joint
committee. Risk factors for heart failure in diabetics treated
with TZDs are summarized in Table 4.
Mechanism of fluid retention
Until recently, the mechanism by which TZDs cause fluid
retention has been obscure. It had been speculated that
multiple factors, such as arterial vasodilation, endothelial
permeability, and renal Naþ reabsorption contributed to this
effect. Nearly a decade ago, Guan et al.16 determined the
localization of PPARs within the kidney. In situ hybridization
revealed that PPAR-a mRNA was expressed in the proximal
tubule and the medullary thick ascending limb, whereas
PPAR-g was expressed exclusively in the medullary collecting
duct. Because the collecting duct plays a critical role in the
regulation of sodium balance, this finding was highly
suggestive of a PPAR-g-mediated contribution to distal
sodium reabsorption.
PPAR-c and the sgk1–Nedd4-2–ENaC pathway
Expression and activity of the epithelial sodium channel
(ENaC) constitute the rate-limiting step for Naþ transport
across the collecting duct epithelium. ENaC is localized at the
apical cell membrane of the principal cell within the
collecting duct of the distal nephron. Its synthesis and
activity are regulated by aldosterone in response to fluctua-
tions in effective arterial blood volume and activation of the
renin–angiotensin–aldosterone axis. It is composed of three
subunits, designated ENaC-a, -b, and -g.17 Maintenance of
electroneutrality during sodium transport across the collect-
ing duct epithelium is made possible by potassium secretion
into the tubular lumen via the renal outer medullary
K channel, which is also under the effect of aldosterone.
The central role of ENaC in the maintenance of Naþ balance
is exemplified by certain forms of hereditary hypertension,
such as Liddle’s syndrome. The study of this syndrome led to
the discovery of the ENaC regulatory pathway and has
contributed to our understanding of the molecular mechan-
isms of Naþ and volume homeostasis. Liddle’s syndrome is a
monogenic disorder, which results from mutations in the PY
motif of the ENaC-a or -g subunits. Normally the PY motif
interacts with the ubiquitin ligase Nedd4-2, leading to
endocytosis and degradation of the ENaC complex. Muta-
tions within the PY motif result in the ENaC complex being
protected from inactivation, resulting in constitutive Naþ
reabsorption and volume-dependent hypertension. Several
proteins interact with or modify Nedd4-2 function. One of
them, the serum- and glucocorticoid-inducible kinase 1
(sgk1) is of special interest as it appears to be regulated by
both aldosterone and insulin.18
Table 3 | PPAR isoforms, expression sites, and available agonists2
Receptor: Expression sites Agonist effect Available agonists
PPAR-a Main sites: liver and skeletal muscle. Other:
heart muscle, vascular smooth muscle, and
endothelium
Lipid-lowering effect, increased fatty acid
uptake and catabolism, anti-inflammatory
effect, prevent or retard atherosclerosis in
mice and humans
Fenofibrate
Bezafibrate
Ciprofibrate
Gemfibrozil
PPAR-g Main site: adipose tissue. Other: renal
medullary collecting ducts, endothelium,
pancreatic-b cells, and at low levels in
muscle and liver cells
Increased insulin-dependant glucose
uptake (insulin-sensitizing effect),
increased fatty acid uptake and storage,
increased adipocyte differentiation,
increased subcutaneous adipose tissue
mass, decreased iNOS, increased collecting
duct ENaC expression and Naþ
reabsorption
Troglitazone
(pure g action)
Rosiglitazone
(pure g action)
Pioglitazone
(some a activity)
Muraglitazar
(dual a–g agonist)
PPAR-delta Skin, brain, adipose tissue, and at low level
in multiple other tissues
Poorly defined Experimental only
ENaC, epithelial sodium channel; iNOS, inducible nitric oxide synthase; PPAR, peroxisome proliferator-activated receptor.
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Sgk1 is a member of the serine/threonine protein kinase
family and is expressed in the distal nephron. Basal levels of
sgk1 are maintained by glucocorticoids,19 but aldosterone
can rapidly stimulate sgk-1 mRNA expression.20 After
synthesis and activation by phosphorylation, sgk1 interacts
with and inactivates Nedd4-2 by phosphorylation. In this
way, Nedd4-2 is prevented from interacting with ENaC’s PY
motif, resulting in decreased ENaC degradation.21 In
addition, sgk1 stimulates the activity of basolateral
NaþKþ -ATPase,22 thus facilitating Naþ reabsorption at
both apical and basolateral sites. In addition, sgk1 activation
has been shown to be partly dependent on the insulin
signaling pathway via the intermediate phosphatidylinositol
3-kinase and 3-phosphoinositide-dependent kinase. Specific
phosphatidylinositol 3-kinase inhibition in renal cell lines
prevents mineralocorticoid-induced sgk1 activation and
subsequent ENaC-mediated Naþ transport.18 Sgk1 knockout
mice are normotensive and demonstrate normal Naþ
balance on standard dietary Naþ intake. In contrast,
Naþ deprivation unmasks their impaired ability to reabsorb
Naþ despite high serum aldosterone levels, resulting in
volume depletion, hypotension, and decreased glomerular
filtration rate.23 The major elements of Sgk-1–Nedd4-2–ENaC
pathway are illustrated in the left-hand panel of Figure 2.
The first report describing PPAR-g interaction with this
pathway came from Hong et al.24 These authors demon-
strated that sgk1 activity is stimulated by treatment of a
human cortical collecting duct cell line with PPAR-g agonists.
The activity of sgk1 paralleled an increase in sgk1 mRNA and
was followed by an increase in cell surface ENaC-a
expression. This effect was abolished by pretreatment with
a specific PPAR-g antagonist. Electrophoretic mobility shift
assay suggested that these effects were caused by binding of
PPAR-g to a specific response element within the sgk1 gene
promoter. Therefore, it appeared that the gene for sgk1 is a
direct target for PPAR-g transactivation.
More recently, Guan et al.25 used an alternative method to
investigate the effect of PPAR-g activation on ENaC
expression. They utilized Cre-loxP recombination metho-
dology to create mice with site-specific knockout of the
PPAR-g gene within the renal cortical collecting duct. Unlike
wild-type controls, mice lacking PPAR-g in the collecting
duct did not increase their body weight after treatment with
pioglitazone. Moreover, they demonstrated diminished
sodium avidity compared to wild-type mice when placed
on a low-salt diet, in spite of elevated basal aldosterone levels.
Further experiments evaluating amiloride-sensitive Naþ flux
in cultured collecting duct cells confirmed that after Cre-
mediated deletion of the PPAR-g gene, Naþ flux was no
longer stimulated by pioglitazone. Moreover, the authors
demonstrated that pioglitazone increased mRNA expression
of the ENaC-g subunit, which preceded the detectable
increase in Naþ flux. The increase in mRNA levels was not
abolished by inhibition of protein synthesis with puromycin,
which suggests that the ENaC-g gene is a direct target
activated by PPAR-g, not dependant on the synthesis of other
transcription factors. Prior studies showed that the expres-
sion of the g-subunit is particularly important for trafficking
and regulation of ENaC expression at the cell membrane.26
Interestingly, in contrast to the study by Hong et al., these
authors did not find evidence for increased sgk mRNA
expression in response to PPAR-g activation. The illustration
of the postulated PPAR-g effects is provided in the right-hand
panel of Figure 2.
Potential treatment strategies
The above findings suggest that targeted ENaC inhibition via
direct receptor blockade (amiloride) or inhibition of channel
synthesis and activity (spironolactone) may be particularly
effective in preventing or treating TZD-induced edema.
Interestingly, a recent study investigating the efficacy of
different diuretic classes in patients who developed fluid
retention in response to TZDs demonstrated that spirono-
lactone in comparison with either furosemide or hydrochlor-
othiazide led to a greater diuretic response in patients who
continued their TZD in spite of evidence of weight gain.27
Outcome measures in this study included changes in weight,
total body water, and extracellular fluid volume as deter-
mined by non-invasive bioelectrical impedance, and changes
in hematocrit, as a surrogate marker for changes in plasma
volume. Unfortunately, these investigators did not include
amiloride, a specific ENaC blocker, as one of the treatment
arms. In the mouse model, amiloride effectively prevents
pioglitazone-induced fluid retention.25 Although similar data
with amiloride are lacking thus far in humans, such an
approach is physiologically intuitive and may prove to be
more useful than the use of loop diuretics acting within the
thick ascending limb. Future clinical research may help
confirm this hypothesis.
SUMMARY AND RECOMMENDATIONS
Recent discoveries indicate that PPAR-g stimulation is
important in the regulation of Naþ balance. The endogenous
activator(s) of PPAR-g in the collecting duct remain
unknown, but its pharmacologic agonists demonstrate a
significant effect on sodium and volume homeostasis.
Table 4 | Risk factors for heart failure in patients treated with
TZDsa
1. History of systolic or diastolic heart failure
2. History of CAD
3. Hypertension
4. LVH
5. Aortic or mitral valvular disease
6. Advanced age (470 years)
7. Long standing diabetes (410 years)
8. Preexisting edema or loop diuretic therapy
9. Development of edema on TZD therapy
10. Insulin co-administration
11. Chronic kidney disease (Cr42.0 mg/dl)
CAD, coronary artery disease; LVH, left ventricular hypertrophy; TZD, thiazolidine-
dione.
aAdapted from the AHA and ADA Joint Consensus Statement.11
766 Kidney International (2007) 72, 762–768
t h e r e n a l c o n s u l t K Kiryluk and R Isom: Thiazolidinediones and fluid retention
Whether the main effect of PPAR-g agonists is mediated by
transactivation of the genes encoding sgk-1, ENaC-g, or both,
remains uncertain. Although the clinically observed increased
incidence of weight gain, edema, and CHF in patients on
combined TZD/insulin therapy has been attributed to these
patients generally having a greater number of traditional risk
factors for development of CHF compared to non-insulin-
treated patients, we have reviewed how the recently
discovered synergistic interaction between the insulin signal-
ing pathway and PPAR-g-mediated sgk1 activation may, in
part, account for this effect.
We recommend adherence to the guidelines put forward
by the American Heart Association and the American
Diabetes Association regarding initiation of TZD use in at-
risk patients. Patients started on a TZD should be followed
closely for weight gain or development of edema or
symptoms of CHF. Clinicians understandably may be
reluctant to discontinue TZDs if their use in specific patients
is accompanied by significant improvement in glycemic
control. Modest increases in weight not accompanied by
symptomatic CHF potentially can be managed successfully by
instituting a diuretic regimen specifically targeting ENaC-
mediated sodium reabsorption (amiloride or spironolac-
tone), without necessarily discontinuing the TZD. Significant
weight gain or new onset/worsening CHF in TZD-treated
patients should prompt discontinuation of the TZD and
initiation of appropriately aggressive supportive measures.
UPDATE
The newly released meta-analysis of 42 randomized trails
revealed that rosiglitazone was associated with a small but
statistically significant risk of myocardial infarction (odds
ratio (OR) 1.43 with 95% confidence interval (CI): 1.03–1.98)
and with an increase in the risk of death from all
cardiovascular causes of borderline significance (OR 1.64
with 95% CI: 0.98–2.74).28 It is currently unclear if these
adverse cardiovascular outcomes are in any way related to
fluid retention and CHF in the rosiglitazone-treated patients.
Since expansion of intravascular volume increases left
ventricular stress and myocardial oxygen demand, it is
theoretically possible that such a causal link exists. It is also
unclear if this effect is specific to rosiglitazone, or if it
represents a class effect of all PPAR-g agonists. Until further
data becomes available, clinicians must be aware of these
potential risks and need to carefully consider alternative
treatments in susceptible type 2 diabetics.
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Figure 2 | Aldosterone and Sgk1–Nedd4-2–ENaC Pathway (left)
and effects of PPAR-c activation (right). Aldosterone interacts with
its mineralocorticoid receptor (MR) and directly upregulates the
mRNA levels of ROMK, ENaC-a, and Sgk-1. Sgk-1 inactivates Nedd4-2,
stimulates basolateral NaþKþATP-ase, and activates ROMK (data not
shown in this panel). The right panel illustrates a possible
convergence point of the insulin and TZD-mediated pathways at
Sgk-1 level. Thiazolidinediones (TZDs) activate PPAR-g, which in turn
increases the expression of ENaC-g and inactive form of Sgk-1
(although not confirmed by Guan et al.). Insulin acts via
phosphatidylinositol 3-kinase (PI3K) and phosphoinositide-
dependant kinase (PDK) pathway which converts inactive Sgk-1 to its
active form by phosphorylation. *the PY motif-mediated interaction
between ENaC subunits and ubiquitin ligase Nedd4-2.
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